Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Concerns About Methodology of a Trial Investigating Vaginal Health During Aromatase Inhibitor Therapy for Breast Cancer

Concerns About Methodology of a Trial Investigating Vaginal Health During Aromatase Inhibitor... Letters Funding/Support: Dr Yao is supported by National Institutes of Health (NIH) Importantly, the beneficial clinical results observed with grants R01 CA166701 and R03 CA192205, and Susan G. Komen Foundation use of aromatase inhibitors over tamoxifen relate to the CCR12225973. Dr Ambrosone is supported by NIH grants P01 CA151135, U01 highly potent third-generation compounds exemestane, CA195565, P30 CA16056, and Breast Cancer Research Foundation. Dr Kushi is anastrozole, and letrozole. First- and second-generation supported by NIH grants R01 CA105274, U01 CA195565, R01 CA172855, and U24 CA171524. compounds such as aminoglutethimide and formestane did 1. Yao S, Kwan ML, Ergas IJ, et al. Association of serum level of vitamin D at not reveal any superiority. The difference in on-treatment diagnosis with breast cancer survival: a case-cohort analysis in the Pathways aromatase inhibition between the second- and third- Study. JAMA Oncol. 2017;3(3):351-357. generation inhibitors that underpins these clinical differ- 2. Goodwin PJ, Ennis M, Pritchard KI, Koo J, Hood N. Prognostic effects of ences in efficacy relates to moderate differences in aromatase 25-hydroxyvitamin D levels in early breast cancer. J Clin Oncol. 2009;27(23): inhibition (90% vs 98%) and in plasma estradiol level of only 3757-3763. 1to2pg/mL. 3. Lappe J, Watson P, Travers-Gustafson http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Oncology American Medical Association

Concerns About Methodology of a Trial Investigating Vaginal Health During Aromatase Inhibitor Therapy for Breast Cancer

JAMA Oncology , Volume 3 (8) – Aug 20, 2017

Loading next page...
 
/lp/american-medical-association/concerns-about-methodology-of-a-trial-investigating-vaginal-health-ilGUQjJybz
Publisher
American Medical Association
Copyright
Copyright 2017 American Medical Association. All Rights Reserved.
ISSN
2374-2437
eISSN
2374-2445
DOI
10.1001/jamaoncol.2017.2071
Publisher site
See Article on Publisher Site

Abstract

Letters Funding/Support: Dr Yao is supported by National Institutes of Health (NIH) Importantly, the beneficial clinical results observed with grants R01 CA166701 and R03 CA192205, and Susan G. Komen Foundation use of aromatase inhibitors over tamoxifen relate to the CCR12225973. Dr Ambrosone is supported by NIH grants P01 CA151135, U01 highly potent third-generation compounds exemestane, CA195565, P30 CA16056, and Breast Cancer Research Foundation. Dr Kushi is anastrozole, and letrozole. First- and second-generation supported by NIH grants R01 CA105274, U01 CA195565, R01 CA172855, and U24 CA171524. compounds such as aminoglutethimide and formestane did 1. Yao S, Kwan ML, Ergas IJ, et al. Association of serum level of vitamin D at not reveal any superiority. The difference in on-treatment diagnosis with breast cancer survival: a case-cohort analysis in the Pathways aromatase inhibition between the second- and third- Study. JAMA Oncol. 2017;3(3):351-357. generation inhibitors that underpins these clinical differ- 2. Goodwin PJ, Ennis M, Pritchard KI, Koo J, Hood N. Prognostic effects of ences in efficacy relates to moderate differences in aromatase 25-hydroxyvitamin D levels in early breast cancer. J Clin Oncol. 2009;27(23): inhibition (90% vs 98%) and in plasma estradiol level of only 3757-3763. 1to2pg/mL. 3. Lappe J, Watson P, Travers-Gustafson

Journal

JAMA OncologyAmerican Medical Association

Published: Aug 20, 2017

References